What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies
Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.
Pharma & Biotech
Features & Analysis
Why Scilex Holding Company sees strategic optionality in diagnostic platforms beyond traditional therapeutics
Explore what Scilex Holding Company’s $20M Quantum Scan investment means for preventive diagnostics and the execution risks ahead.
Medical Devices & Diagnostics
Why UVDI’s new V-MIX air disinfection system could reshape HVAC pathogen control
Find out how UVDI’s V-MIX UV-C disinfection system is pushing upper-room air safety beyond hospitals into schools, offices, and airports.
Pharma & Biotech
What Vetter Pharma’s Saarland project reveals about long-cycle CDMO investment strategies
Vetter Pharma commits €480M to build a new commercial injectable manufacturing site in Saarland, Germany; explore industry impact and CDMO capacity shifts.
Pharma & Biotech
What Quince’s failed NEAT trial reveals about rare pediatric trial design risks
Quince Therapeutics ends clinical development of eDSP for A-T after Phase 3 failure. Find out what this means for its platform and future strategy.
Medical Devices & Diagnostics
What KORU Medical’s RYSTIGGO delivery clearance means for subcutaneous infusion models
KORU Medical’s FreedomEDGE gets FDA clearance for RYSTIGGO delivery in clinics. Find out how this expands access to gMG therapy and reshapes infusion workflows.
Pharma & Biotech
Is Biocodex’s Fullify the first probiotic to challenge GLP-1 drugs in the consumer weight-loss space?
Biocodex launches Fullify, a gut-brain axis probiotic for appetite control. Find out what this means for weight loss, microbiome science, and the supplement industry.
Pharma & Biotech
How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences
Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.
Pharma & Biotech
Tenpoint’s YUVEZZI sets new benchmark in presbyopia eye drop efficacy and safety
YUVEZZI becomes the first FDA-approved dual-agent eye drop for presbyopia. Find out what this means for Tenpoint Therapeutics and the future of vision care.
Pharma & Biotech
Sinomune to launch Almirall’s Seysara in China: Can it reshape acne treatment models?
Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.